Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference135 articles.
1. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C (2017) Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(1):60–87
2. Bewersdorf JP, Zeidan AM (2019) Transforming growth factor (TGF)-beta pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia. 33(6):1303–1312
3. Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X (2019) Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev 34:1–15. https://doi.org/10.1016/j.blre.2018.09.001
4. Santini V (2019) How I treat MDS after hypomethylating agent failure. Blood 133(6):521–529. https://doi.org/10.1182/blood-2018-03-785915
5. Platzbecker U (2019) Treatment of MDS. Blood 133(10):1096–1107. https://doi.org/10.1182/blood-2018-10-844696
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献